Thomas B. Neff Sells 18,900 Shares of FibroGen, Inc (FGEN) Stock
FibroGen, Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 18,900 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $54.45, for a total transaction of $1,029,105.00. Following the completion of the transaction, the chief executive officer now directly owns 3,217,455 shares of the company’s stock, valued at approximately $175,190,424.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of FibroGen, Inc (FGEN) traded down 1.93% during mid-day trading on Friday, hitting $54.75. 409,180 shares of the stock traded hands. The firm’s market cap is $3.90 billion. The firm’s 50 day moving average price is $51.76 and its 200 day moving average price is $36.23. FibroGen, Inc has a 12-month low of $15.60 and a 12-month high of $60.15.
FibroGen (NASDAQ:FGEN) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.01). FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%. The firm had revenue of $29.00 million for the quarter, compared to analyst estimates of $34.80 million. On average, equities research analysts predict that FibroGen, Inc will post ($1.81) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Thomas B. Neff Sells 18,900 Shares of FibroGen, Inc (FGEN) Stock” was originally reported by Marea Informative and is the sole property of of Marea Informative. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at http://www.mareainformativa.com/fibrogen-inc-fgen-ceo-thomas-b-neff-sells-18900-shares/117582/.
A number of institutional investors and hedge funds have recently bought and sold shares of FGEN. Ameritas Investment Partners Inc. acquired a new stake in FibroGen in the 1st quarter worth approximately $111,000. Quantbot Technologies LP acquired a new stake in FibroGen in the 2nd quarter worth approximately $128,000. SG Americas Securities LLC lifted its holdings in FibroGen by 6.5% in the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 412 shares during the last quarter. Amalgamated Bank acquired a new stake in FibroGen in the 2nd quarter worth approximately $237,000. Finally, BNP Paribas Arbitrage SA lifted its holdings in shares of FibroGen by 589.1% during the second quarter. BNP Paribas Arbitrage SA now owns 7,401 shares of the biopharmaceutical company’s stock worth $239,000 after buying an additional 6,327 shares during the last quarter. Hedge funds and other institutional investors own 47.49% of the company’s stock.
A number of research firms have recently weighed in on FGEN. Leerink Swann reiterated an “outperform” rating and issued a $82.00 price objective (up previously from $52.00) on shares of FibroGen in a research note on Tuesday, August 8th. William Blair reiterated an “outperform” rating on shares of FibroGen in a research note on Wednesday, August 9th. Jefferies Group LLC restated a “buy” rating and set a $75.00 price target on shares of FibroGen in a research report on Tuesday, August 8th. Mizuho began coverage on shares of FibroGen in a research report on Wednesday, October 4th. They set a “neutral” rating and a $61.00 price target on the stock. Finally, Citigroup Inc. raised their price target on shares of FibroGen from $48.00 to $65.00 and gave the company a “top pick” rating in a research report on Tuesday, August 8th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. FibroGen has an average rating of “Buy” and a consensus price target of $65.67.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Stock Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related stocks with our FREE daily email newsletter.